{{Rsnum
|rsid=6603859
|Gene=C1orf144
|Chromosome=1
|position=16379580
|Orientation=plus
|GMAF=0.4417
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=SZRD1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 26.2 | 44.6 | 29.2
| HCB | 4.4 | 33.3 | 62.2
| JPT | 4.5 | 43.2 | 52.3
| YRI | 41.3 | 41.3 | 17.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 4.4 | 33.3 | 62.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6603859
|Name_s=
|Gene_s=C1orf144
|Feature=
|Evidence=PubMed ID:18451141
|Annotation=This SNP on chromosome 1 was associated with the susceptibility to daunorubicin-induced cytotoxicity in the YRI population using International HapMap cell lines.
|Drugs=daunorubicin
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA162263547
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6603859
|overall_frequency_n=61
|overall_frequency_d=128
|overall_frequency=0.476562
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=54
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}